Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.

BMC cancer - 17 Feb 2020

Miele Evelina, Abballe Luana, Spinelli Gian Paolo, Besharat Zein Mersini, Catanzaro Giuseppina, Chiacchiarini Martina, Vacca Alessandra, Po Agnese, Capalbo Carlo, Ferretti Elisabetta

Abstract excerpt

BACKGROUND: Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient's survival. However, BRAF-mutated CRC patients remain unresponsive to available therapies with RAF inhibitors (RAFi) alone or combined with ErbB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Molecular Targeted Therapy

Share to Panitumumab

Share to Proto-Oncogene Proteins B-raf

Share to Receptor, ErbB-2

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 32066410
DOI: 10.1186/s12885-020-6586-0
PMCID: PMC7027203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.PMID 32066410Read ↗

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAFi/ErbB1 inhibitorsSemantic proximity Read ↗

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.Semantic proximity Read ↗

Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.Semantic proximity Read ↗

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.Semantic proximity Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.